Bailard’s Atea Pharmaceuticals AVIR Stock Holding History

Bailard’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24,400	Closed	-$218K	–	728
2021 Q4	$218K	Buy	+24,400	New	+$380K	0.01%	662

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bailard's AVIR Position: Q1 2022 in Review

Bailard sold out of Atea Pharmaceuticals (AVIR) in Q1 2022, closing a stake of 24,400 shares — an estimated $218K sold.

Bailard first reported a position in AVIR in Q4 2021 and held it in 1 quarter. The position peaked at $218K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2022.

Bailard reported no remaining Atea Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Bailard sold 24,400 Atea Pharmaceuticals shares in Q1 2022, an estimated $218K.
Bailard first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Bailard's Atea Pharmaceuticals position peaked at $218K in Q4 2021.
127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.